三鑫医疗：人工血管项目进入多中心临床试验阶段，有望填补国内空白

Core Insights - The company, Sanxin Medical, has announced that its domestically developed integrated artificial blood vessel project made from expanded polytetrafluoroethylene has entered the multi-center clinical trial phase nationwide, accelerating the recruitment of participants [2] - This product is primarily designed for the long-term vascular access construction for patients undergoing hemodialysis, referred to as the "lifeline" for dialysis patients [2] - The product is expected to fill a gap in the domestic market upon its launch, addressing urgent clinical needs [2]